This is challenging as the encapsulation procedure subjects the cells to further stress because cells are sheared through drain tubes and are influenced by changes in the osmotic environment and other stresses. commercially available enzymes (AccutaseTM, Chlorothiazide TrypZeanTM) that fulfill all process requirements (commercial availability, cost, GMP conditions during developing and nonanimal source) are found to be generally suitable for detaching hMSC-TERT. Combining cell detachment with encapsulation shown a high effect of the experimental setup on cell damage. It was preferable to reduce the temp during detachment and limit the detachment time to a maximum of 20 moments. Cell detachment in static systems was not similar with detachment in dynamic systems. Detachment yields in dynamic systems were lower and cell damage was higher for the Chlorothiazide same experimental conditions. Finally, only TrypZeanTM seemed to be suitable for the detachment of hMSC-TERT from dynamic reactor systems. Keywords:ATMP, bioreactor, enzymatic detachment, glass carrier, hMSC. == 1. Intro == Stem cells are probably one of the most important tools in cell therapy. They can be used to treat many diseases including diabetes mellitus and stroke [1]. In particular, human being mesenchymal stromal cells (hMSC) are highly promising for further applications in cell therapy. One example of the use of hMSCs in cell therapy is the CellBeadtechnology (CellMed AG, a subsidiary of BTG plc.). CellBeadis an implantable cell restorative system based on a genetically revised hMSC cell collection (hMSC-TERT) encapsulated in Chlorothiazide alginate, and is under a medical trial for stroke treatment (medical trial quantity:NCT01298830). The microcapsules enable the application of allogeneic stem cells Chlorothiazide without graft-versus-host-disease [2]. As stem cells become progressively important for restorative treatments, enormous amounts of these cells will need to be produced. This is essential, because hMSCs only grow in adherent tradition. Based on a restorative dose ranging from 1.5 to 120 106hMSCs [3] and a maximum expansion of 100,000 hMSCs per cm2, a growth surface of between 10 and 1,200 cm2is required for a single dose. When using allogeneic hMSCs, the cell restorative can be produced as a stock. In this case, one production process should yield 100 doses. This means that a growth surface as large as 120,000 cm2could be required, related to 400 T-300 flasks to produce only 100 doses. Related amounts of cells can be very easily acquired using one 6.4 L fixed bed reactor or one 22 L stirred tank reactor. Bioreactors present advantages including low staff demand, high space-time yield, a high level of automation of the cultivation, and a high level of control over the cell harvest and process control [4]. In conclusion, bioreactors should be the system of choice for hMSC development. The hMSC production process is special in that the expanded cell is the product itself. In standard processes such as antibody production, the production cells are discarded at the end of the process. Inside a stem cell development process, the production cell has to be harvested and removed from the reactor vessel in a high amount and at a high viability. In this study, the hMSC-TERT cell collection was COG3 used as a representative of therapeutically applied hMSCs. As hMSC-TERT are adherently growing cells, carriers can be used to provide a appropriate growth surface for any bioreactor development [5]. For the hMSC-TERT development processes with this work, non-porous and uncoated glass service providers were chosen. These carriers have been shown to be ideal as they on the Chlorothiazide one hand promote plenty of cell attachment and cell growth for an efficient development and on the other hand enable cell detachment [5]. This is not naturally given for those carriers as most of them are only optimized for strong cell adherence but not for cell detachment. With appropriate carriers hMSC can be expanded in several cultivation systems. Many are known for his or her applicability to hMSC development, including fixed bed systems [4,6,7] and stirred tank reactors [3,8]. The common characteristic of all hMSC development systems is that the adherent stem cells have to be detached from your growth surface at the end of the development process. One standard method of hMSC detachment is definitely proteolytic cleavageviaproteases. The cell adherencein vitrois based on peptide bonds created between medium proteins and extracellular cell surface proteins [9]. Positive charged medium proteins (primarily serum proteins as fibronectin (pI 5.3)) adsorb to the bad charged plastic or glass surface types. Based on electrostatic relationships bad charged cells stick to the medium proteins. Finally covalent bonds were created between the protein surface coating and integrins within the cell surface. As a consequence of this mode of attachment, adherent cells can be detachedviaproteolytic.